Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods

Executive Summary

Fallout from the withdrawal of Vioxx (rofecoxib) will likely have an impact on post-marketing surveillance methods for COX-2 inhibitors and other drugs

You may also be interested in...



Interview: CrystalGenomics, First Korean Bioventure To ‘Go All The Way’

After reaching milestones by launching a novel osteoarthritis drug and licensing out an AML candidate to a US partner, CrystalGenomics’ CEO talks to Scrip about what else is in store for the South Korean bioventure in 2017 and beyond.

Celebrex Study Is Feel Good Story For Pfizer, But Are There Any Real Benefits?

Companies with pipeline pain products may see a smoother path through FDA, but Celebrex already has generic competition in the US, limiting the benefits even if it could get the black box removed from labeling and Pfizer also recently settled a lawsuit for $468 million related to the drug's safety.

NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim

Does wide public health concern warrant flexibility in regulatory standards for safety claims? An advisory panel on cardiovascular risk of NSAIDs spotlights the dual challenge of accurately determining drug risks and communicating risks in informative way.

Related Content

UsernamePublicRestriction

Register

PS044779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel